The text starts here.

News Release

FOR IMMEDIATE RELEASE
September 3, 2010
For Print (PDF 67KB)

EISAI TO LAUNCH RAPID-ACTING INSULIN SECRETAGOGUE GLUFAST® IN CHINA


Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced today that it launched Glufast® (Chinese brand name: Kuai ru tuo, generic name: mitiglinide calcium hydrate), a rapid-acting insulin secretagogue, in China on September 1. Glufast® is a phenylalanine derived rapid-acting insulin secretagogue originally discovered and developed by Kissei Pharmaceutical Co., Ltd. (Headquarters: Matsumoto, Nagano, President & CEO: Mutsuo Kanzawa, “Kissei”).

Eisai obtained the exclusive rights to develop and commercialize Glufast® in China through a license agreement it concluded with Kissei in September 2007. Developed in China by Kissei and approved by the Chinese health authorities in November 2009, Glufast® will be sold by Eisai's Chinese subsidiary Eisai China Inc. (Suzhou, Jiangsu). Kissei and Eisai also concluded a license agreement in June 2007 to develop and commercialize Glufast in 10 ASEAN countries.

Glufast® promotes insulin secretion by stimulating the sulfonylurea receptors (SUR1) located on pancreatic islet beta cells. Marketed in Japan since 2004, the drug is indicated for the improvement of postprandial blood glucose transition in type II diabetic patients. Glufast® lowers elevated post-meal blood glucose levels by restoring insulin secretion close to its natural patterns with a faster onset of action than sulfonylurea insulin secretion stimulants (SU drugs). Furthermore, compared with SU drugs, Glufast® is less likely to trigger hypoglycemia because of its short duration of action.

Eisai has focused its efforts in China on the development of the peripheral neuropathy treatment Methycobal® and other diabetes treatments such as -Lipon 300 STADA®, a treatment for diabetic neuropathic pain. Through the addition of Glufast®, Eisai not only hopes to strengthen its portfolio of diabetes treatments, it also intends to increase synergy of these three products as its strives to establish a presence in the diabetes therapeutic area and seeks to make further contributions to addressing the diversified needs of and increasing benefits provided to diabetes patients and their families.


Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120